Merck opens US $1 billion facility to boost bladder cancer treatment

USA – Merck has inaugurated a new vaccine manufacturing facility in Durham, North Carolina, to produce a critical bladder cancer treatment.

This US $1 billion, 225,000-square-foot plant will manufacture the Bacillus Calmette-Guérin (BCG) vaccine, an essential therapy for early-stage bladder cancer.

The vaccine contains a weakened strain of tuberculosis-causing bacteria and has been widely used to prevent the disease from worsening.

Merck’s decision to build this facility dates back five years when there was a global shortage of the BCG vaccine.

The opening comes amid increasing efforts to expand manufacturing within the United States, reducing reliance on overseas production. This strategy aligns with policies aimed at strengthening domestic pharmaceutical manufacturing.

The new facility is part of Merck’s larger plan to expand its U.S. production capabilities. Since 2018, the company has invested over US $12 billion in manufacturing and research and development. Merck also plans to invest an additional US $8 billion in similar efforts by 2028.

According to Merck, the plant features the latest technological advancements, including artificial intelligence, data analytics, and 3D printing. These innovations are expected to enhance efficiency and streamline vaccine production.

In addition to this investment, Merck recently secured a US $30 million strategic fund from Delaware’s Division of Small Business.

The company is exploring the possibility of establishing a new commercialization and launch facility in the state to support its expanding pharmaceutical operations.

Merck’s new facility is a significant step in ensuring a stable supply of the BCG vaccine, which is essential for bladder cancer patients.

“This investment underscores our commitment to addressing critical treatment shortages and advancing cancer care,” the company stated.